Tiziana Doses Final Patient in Phase 2a INFORM-MS Trial for Foralumab; Topline Data Due October 2026

Tiziana Life Sciences Ltd. (TLSA) said on Monday it dosed the final patient in the Phase 2a INFORM-MS trial of Foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The biotechnology company expects topline data from the trial in October 2026. Completion of enrollment and dosing positions the study for its next data readout. Tiziana did not disclose additional clinical results or financial terms in the announcement.